GE HealthCare’s comprehensive approach to breast cancer care addresses key challenges with new offerings to support personalized breast care

  • •    New MyBreastAI Suite* supports clinicians in accelerating breast cancer detection
  • •    Latest Pristina Bright** offering provides a comprehensive solution to help healthcare providers start a new contrast program

With breast cancer now surpassing lung cancer as the most commonly diagnosed cancer worldwide,<sup1<>>clinicians are seeking tools that can address issues related to access, burnout, variability, and cost in breast imaging to not only enhance the detection and diagnosis of breast cancers, but also help improve overall patient outcomes.</sup1<>

Leveraging artificial intelligence to support clinicians in accelerating breast cancer detection

The introduction of MyBreastAI Suite* at RSNA2023 aims to address these challenges by providing an all-in-one platform that integrates a comprehensive collection of artificial intelligence (AI) tools that can seamlessly deploy AI to breast imaging workflow.

With this initial release, MyBreastAI Suite integrates three AI applications from iCAD including

ProFound AI for DBT, PowerLook Density Assessment, and SecondLook for 2D Mammography to help support early detection and improve patient outcomes, as well as help radiology departments improve operational productivity.

A “brighter” future for patients and providers

Contrast-Enhanced Mammography (CEM) is a game changer in breast diagnostic imaging and biopsy care. GE HealthCare pioneered this technology in 2010 and is associated with over 200 publications that demonstrate its clinical performances. The company’s CEM combines the morphologic and density information similarly to a conventional mammogram and the functional vascular information of a breast MRI.2

In an effort to help further advance breast cancer and support healthcare providers in a starting a new contrast program, GE HealthCare’s latest Pristina Bright** offering provides a comprehensive solution. Pristina Bright combines

SenoBright HD, Pristina Serena, and Serena Bright with an education program that includes dedicated on-site support, CME accredited self-assessment, as well as access to the users’ club where providers will be able to share with experts around the globe and leverage resources needed to market their facility among referring doctors and patients.

With Pristina Bright, clinicians can see lesions that cannot be seen on routine mammography3 4 5 and biopsy what is seen within 15 minutes.6 To help improve overall productivity, Pristina Bright can help also providers take more patients on their system, with the ability to image up to 30 patients a day with contrast mammography7 through an easy-to-read exam.

Personalized breast care and supplemental imaging

40% of women have dense breast tissue - which means they have a higher proportion of fibro glandular tissue than fatty tissue. While mammography is considered the most reliable imaging technique for breasts, limitations can exist due to breast density. This is especially the case in dense breasts where tissues may overlap - hiding signs of breast cancer and making diagnosis more difficult or even missed.

To provide a personalized breast screening approach for a diverse population, including those with dense breasts, GE HealthCare offers a comprehensive portfolio of breast imaging technologies, including the Senographe Pristina, a mammography system designed to provide a better patient experience,8 and optimized for rapid diagnosis, while also delivering superior diagnostic accuracy compared to 2D alone for all types of breast densities, including dense breasts.

In addition to screening mammography, the company’s Invenia ABUS is the first FDA-approved automatic breast ultrasound supplemental screening specifically designed for detecting cancer in dense breast.

When a result remains inconclusive after screening, GE HealthCare’s SenoBright HD Contrast Enhanced Mammography (CEM) can provide immediate follow-up when in search for a definitive answer. CEM combines mammography and vascular-based screening methods to highlight areas of unusual blood-flow patterns that may indicate malignancy - helping reduce the masking effect of fibro glandular breast tissue so lesions can be more clearly identifiable. A SenoBright exam can be performed in the same room as a mammogram, with the same equipment, and can even be performed the same day in about seven minutes as part of GE HealthCare’s aim to provide precision, comfort and efficiency across the entire clinical breast health continuum. If medical indications recommend pathology, biopsy under contrast with Serena Bright can also be performed from first image to last image within fifteen minutes.

Collaborating to improve breast cancer outcomes

In addition to this offering and in continued pursuit to improve breast cancer outcomes, GE HealthCare has joined the Contrast-Enhanced Mammography Imaging Screening Trial (CMIST)17 in collaboration with the American College of Radiology (ACR) and the Breast Cancer Research Foundation (BCRF)to gain an increased understanding of the effectiveness of CEM in the detection of breast cancer in dense breasts. The CMIST study seeks to determine if contrast-enhanced mammography provides more accurate cancer detection compared to digital breast tomosynthesis (DBT), including whether it reduces false-positive exams, in women with dense breasts. The study recently reached another significant milestone 18 this year with the opening of the first site and enrollment of first participants at Carolina Breast Imaging Specialists (CBIS) in the United States.

Commitment to access and early detection

As part of this year’s showcase, GE HealthCare’s will have a mobile mammography showcase as part of the company’s commitment to enabling access to healthcare. Attendees will have the unique opportunity to explore the capabilities of this unit designed to offer convenient screening set-up within the familiar environment of a workplace. The truck is equipped with state-of-the-art mammography equipment to ensure accurate and efficient screenings.

The team will also be offering the following programming in the GE Innovation Theater during #RSNA23:

CMIST: Our groundbreaking trial’s most recent updates and insights (November 29, 2023 from 10:30 am CST): Learn more about the Contrast-Enhanced Mammography Imaging Screening trial currently underway – the largest prospective clinical study ever done with contrast mammography through a collaboration between GE HealthCare, American College of Radiology and the Breast Cancer Research Fund, as well as 15 U.S. facilities.

Come visit the GE HealthCare booth in the North Hall (#7326) for more information.

These products may not be available in your country or region. Please contact your GE HealthCare representative for more information.


Emily Niles

*MyBreastAI suite is a commercial offering that includes GE HealthCare’s Edison Health Services platform, ProFound AI® for DBT, SecondLook for 2D Mammography and PowerLook® Density Assessment. These applications are provided by iCAD. MyBreastAI Suite is compatible with the latest versions of iCAD, Inc. as of November 14, 2023. ** Pristina Bright is a commercial offering including SenoBright HD, Pristina Serena and Serena Bright
Bashar, MD Abu; Begam, Nazia1. Breast cancer surpasses lung cancer as the most commonly diagnosed cancer worldwide. Indian Journal of Cancer 59(3):p 438-439, Jul–Sep 2022. | DOI: 10.4103/ijc.IJC_83_21
2 510(k) K172404.
3 Compared to without contrast.
4 Sung JS, et al. Performance of Dual-Energy Contrast-enhanced Digital Mammography for Screening Women at Increased Risk of Breast Cancer. Radiology. 2019 Oct;293(1):81-88.
5 Sorin V, et al. Contrast-Enhanced Spectral Mammography in Women With Intermediate Breast Cancer Risk and Dense Breasts. AJR Am J Roentgenol. 2018 Nov;211(5):W267-W274.
6 Data on file. GE HealthCare 2020.
7 Over 8 hours. Data on file, GE HealthCare 2019.
8 Pisano et al. NEJM 2005; 353: 1773.
9 Buchberger W, Geiger-Gritsch S, Knapp R, Gautsch K, Oberaigner W. Combined screening with mammography and ultrasound in a population-based screening program. Eur J Radiol. 2018 Apr;101:24-29
10 Up to 50% of breast cancers may be missed in extremely dense breasts. Kolb et al, Radiology, Oct 2002;225(1):165-75.
11 Superior diagnostic accuracy demonstrated in a reader study comparing the ROC AUC of GE screening protocol (V--Preview + 3D CC/MLPreview + 3D CC/MLO with 3D in STD mode) to that of 2D FFDM alone.O with 3D in STD mode) to that of 2D FFDM alone.
12 Compared to without contrast
13 J. Sung et al., Radiology 2019; 00:1–8
14 V. Sorin et al. American Journal of Roentgenology: W267-W274. 10.2214/AJR.17.19355
15 Data on file, GE HealthCare 2017
16 Data on file. GE HealthCare 2020